US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Gene Editing

498.91

+35.857.74%

Number of Gainers:5

Number of Losers:- -

Number of Flat:- -

PE:- -

High:502.45

Open:469.68

Low:469.68

Close:463.06

Volume:25.91M

Turnover:266.12M

Market Cap:10.68B

Float Cap:9.79B

Loading ...

Intellia’s New Cell Therapy Alliances Add Optionality To Growth Story

Simply Wall St.

What's Going On With Beam Therapeutics Stock?

Benzinga_recent_news

Intellia Therapeutics to Participate in Upcoming Investor Conferences

Beam Therapeutics announces $500M financing facility

Beam Therapeutics Secures $500 Million Credit Facility

Beam Therapeutics tops Q4 profit estimates, signs financing deal

Beam Q4 net income attributable to common stockholders hits USD 244.3 million

Beam Therapeutics Secures $500 Million Financing Facility With Sixth Street

Beam Therapeutics Inc - Secures up to $500 Mln Non-Dilutive Capital From Sixth Street

THOMSON REUTERS

Beam Therapeutics Inc - Plans Ind Filing for Beam-304 With FDA in 2026

THOMSON REUTERS

Beam Therapeutics Q4 License and Collaboration Revenue USD 114.109 Million

THOMSON REUTERS

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Beam Therapeutics Inc - Credit Facility Matures in 2033 With 10% Interest Rate

THOMSON REUTERS

Press Release: Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

Beam Therapeutics Inc. published an update to their financial calendar

Editas Medicine to Participate in Upcoming Investor Conferences

Beam Therapeutics Initiated at Buy by Canaccord Genuity

Beam Therapeutics initiated with a Buy at Canaccord

Intellia Therapeutics Inc. to Host Conference Call on Q4 and Full-Year 2025 Financial Results and Business Updates

Press Release: ONE Gas Announces Fourth Quarter and Full Year 2025 Financial Results; Releases Non-GAAP Adjusted Financial Guidance

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4556/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":498.913,"timestamp":1771966799999,"preClose":463.06064,"halted":0,"volume":25911061,"delay":0,"changeRate":0.077425,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":35.852356,"latestTime":"02-24 16:00:00 EST","open":469.68347,"high":502.4507,"low":469.68347,"amount":266121768.470129,"amplitude":0.070762,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772029800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.689237,"peRate":-5.615556,"turnoverRate":0.035202,"increases":5,"decrements":0,"flats":0,"marketCap":10680427600,"floatMarketCap":9789982912},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":502.4507,"amplitude":0.070762,"preClose":463.06064,"low":469.68347,"pbRate":"2.689237","latestPrice":498.913,"volume":25911061,"delay":0,"open":469.68347,"prevYearClose":431.70972,"prevWeekClose":453.7237,"prevMonthClose":444.3123,"prevQuarterClose":431.7097,"fiveDayClose":449.1916,"twentyDayClose":483.459,"sixtyDayClose":421.416,"secType":"PLATE","market":"US","turnoverRate":0.035202,"peRate":-5.615556,"marketCap":10680427600,"floatMarketCap":9789982912,"timestamp":1771966799999,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":5,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614071397","title":"Intellia’s New Cell Therapy Alliances Add Optionality To Growth Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2614071397","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614071397?lang=en_us&edition=fundamental","pubTime":"2026-02-25 16:34","pubTimestamp":1772008463,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NasdaqGM:NTLA) has announced new collaborations with AvenCell Therapeutics and Kyverna Therapeutics.\nThe partnerships focus on expanding engineered cell therapies for cancer and autoimmune diseases.\nThese agreements mark a shift in how Intellia aims to apply its gene editing platform across multiple therapeutic areas.\n\nIntellia Therapeutics, traded as NasdaqGM:NTLA, is a gene editing company focused on developing CRISPR based therapies. By teaming up with AvenCell...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellias-new-cell-therapy-alliances-add-optionality-to-grow","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellias-new-cell-therapy-alliances-add-optionality-to-grow","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","LU1861558580.USD","BK4535","LU1861559042.SGD","BK4556","BK4139","NTLA","BK4588"],"gpt_icon":0},{"id":"2614474406","title":"What's Going On With Beam Therapeutics Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2614474406","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614474406?lang=en_us&edition=fundamental","pubTime":"2026-02-25 03:07","pubTimestamp":1771960020,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (NASDAQ: BEAM) shares are rising Tuesday after the company reported quarterly results.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/24/Candlestick-Chart-Showing-Falling-Stock-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/24/Candlestick-Chart-Showing-Falling-Stock-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/02/50828406/whats-going-on-with-beam-therapeutics-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/02/50828406/whats-going-on-with-beam-therapeutics-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4505","LU1861558580.USD","BEAM","LU1861559042.SGD","BK4007","BK4139","BK4556","BK4585","BK4588","BK4611","BK4535","IND","LENZ","BK4539"],"gpt_icon":0},{"id":"2613142917","title":"Intellia Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2613142917","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613142917?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:00","pubTimestamp":1771938000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Feb.  24, 2026  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/24/3243528/0/en/Intellia-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1861559042.SGD","NTLA","BK4585","LU1861558580.USD","BK4556","BK4588","BK4535"],"gpt_icon":0},{"id":"2613719141","title":"Beam Therapeutics announces $500M financing facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2613719141","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613719141?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:36","pubTimestamp":1771936616,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) entered into a strategic financing agreement with Sixth Street for substantial, long-term, non-dilutive capital to fund th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-announces-500m-financing-facility-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-announces-500m-financing-facility-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","LU1861559042.SGD","BK4611","BK4539","BK4588","BK4556","BK4585","BK4535","BEAM","LENZ","BK4007","BK4505","BK4139"],"gpt_icon":0},{"id":"2613173719","title":"Beam Therapeutics Secures $500 Million Credit Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2613173719","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613173719?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:35","pubTimestamp":1771936513,"startTime":"0","endTime":"0","summary":"Beam Therapeutics ( ($BEAM) ) has shared an update. On February 24, 2026, Beam Therapeutics reported fourth-quarter and full-year 2025 financial re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beam-therapeutics-secures-500-million-credit-facility?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beam-therapeutics-secures-500-million-credit-facility?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4611","BK4007","LU1861559042.SGD","BK4539","BK4139","BK4505","BK4556","BK4585","BEAM","LU1861558580.USD","BK4588","BK4535"],"gpt_icon":0},{"id":"2613846716","title":"Beam Therapeutics tops Q4 profit estimates, signs financing deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2613846716","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613846716?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:10","pubTimestamp":1771935052,"startTime":"0","endTime":"0","summary":"Beam Therapeutics tops Q4 profit estimates, signs financing dealOverviewBiotechnology firm reported Q4 EPS and net income beat analyst expectationsCompany entered strategic financing agreement with Si","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL1N3ZK0HD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","LU1861558580.USD","BK4535","BK4611","BK4556","BK4585","BK4505","BK4588","BEAM","BK4139"],"gpt_icon":0},{"id":"2613471529","title":"Beam Q4 net income attributable to common stockholders hits USD 244.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2613471529","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613471529?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:05","pubTimestamp":1771934720,"startTime":"0","endTime":"0","summary":"Beam Q4 net income attributable to common stockholders hits USD 244.3 million               Beam Therapeutics reported Q4 2025 license and collaboration revenue of USD 114.1 million (up 279.5%) and R&","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDLcfW8ZH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","LU2210150020.SGD","IE00BKPKM429.USD","BK4585","LU1861558580.USD","LU2095319765.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4611","SG9999014005.SGD","LU2210149790.SGD","BK4139","SG9999014013.SGD","LU1861559042.SGD","BK4556","BEAM","SG9999014039.USD","BK4588","BK4505","BK4112","LU0314104364.USD","IE00BGHQF748.EUR","NDAQ","SG9999014021.USD"],"gpt_icon":0},{"id":"2613771591","title":"Beam Therapeutics Secures $500 Million Financing Facility With Sixth Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2613771591","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613771591?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:03","pubTimestamp":1771934629,"startTime":"0","endTime":"0","summary":"Beam Therapeutics Inc. entered a $500 million senior secured credit facility with Sixth Street to support the potential launch of its sickle cell disease therapy risto-cel. The facility includes $100 million funded at closing, up to $300 million available upon specified clinical, regulatory and commercial milestones, and an additional $100 million available at Beam’s option subject to mutual agreement. The seven-year facility matures in early 2033, carries an interest rate of about 10% based on current SOFR projections, has no scheduled amortization, and is secured by first-priority liens on substantially all of Beam’s assets.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL6dySKt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","LU2210150020.SGD","IE00BKPKM429.USD","BK4585","LU1861558580.USD","LU2095319765.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4611","SG9999014005.SGD","LU2210149790.SGD","BK4139","SG9999014013.SGD","LU1861559042.SGD","BK4556","BEAM","SG9999014039.USD","BK4588","BK4505","BK4112","LU0314104364.USD","IE00BGHQF748.EUR","NDAQ","SG9999014021.USD"],"gpt_icon":0},{"id":"2613971684","title":"Beam Therapeutics Inc - Secures up to $500 Mln Non-Dilutive Capital From Sixth Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2613971684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613971684?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:01","pubTimestamp":1771934461,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nPLX183866:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861559042.SGD","BK4611","LU1861558580.USD","BK4556","BK4588","BK4505","BK4139","BK4585","BEAM","BK4535"],"gpt_icon":0},{"id":"2613716801","title":"Beam Therapeutics Inc - Plans Ind Filing for Beam-304 With FDA in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2613716801","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613716801?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:01","pubTimestamp":1771934461,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nPLX183866:8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4585","BK4535","BK4611","LU1861558580.USD","BK4556","LU1861559042.SGD","BEAM","BK4139","BK4588"],"gpt_icon":0},{"id":"2613715575","title":"Beam Therapeutics Q4 License and Collaboration Revenue USD 114.109 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2613715575","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613715575?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:01","pubTimestamp":1771934461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nPLX183866:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4535","BEAM","BK4585","BK4588","BK4556","BK4505","LU1861558580.USD","LU1861559042.SGD","BK4611"],"gpt_icon":0},{"id":"2613559719","title":"Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613559719","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613559719?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:01","pubTimestamp":1771934460,"startTime":"0","endTime":"0","summary":"New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM304 Anticipated in 2026 Updated Phase 1/2 Data and Next St","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/24/3243386/0/en/Beam-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Announces-New-Liver-Targeted-Genetic-Disease-Program-in-Phenylketonuria-PKU.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","LU0122379950.USD","BK4533","LU0306806265.USD","SCD","LU0321505439.SGD","SGXZ57979304.SGD","BK4581","LENZ","LU1894683264.USD","BK4505","SG9999001176.USD","LU0225284248.USD","BK4109","BEAM","BK4588","SG9999002224.SGD","BK4556","SG9999002232.USD","BK4535","BK4139","LU0170899867.USD","BK4568","BK4534","LU1894683348.USD","LU0306807586.USD","SG9999001176.SGD","BK4611","LU0289739699.SGD","BK4592","LU1066051498.USD","IE00BBT3K403.USD","BK4539","SG9999011175.SGD","LU0321505868.SGD","LU0868494617.USD","IND","IE000M9KFDE8.USD","LU1023059063.AUD","BK4550","LU0234572021.USD","LU1861558580.USD","LU1883839398.USD","SG9999013999.USD","ASH","BK4599","IE00B19Z3B42.SGD","BK4585","LU0456855351.SGD"],"gpt_icon":1},{"id":"2613716893","title":"Beam Therapeutics Inc - Credit Facility Matures in 2033 With 10% Interest Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2613716893","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613716893?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:00","pubTimestamp":1771934402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA1CVW5J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861559042.SGD","BK4139","BK4585","BK4588","BK4505","LU1861558580.USD","BEAM","BK4556","BK4535","BK4611"],"gpt_icon":0},{"id":"2613571540","title":"Press Release: Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2613571540","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613571540?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:00","pubTimestamp":1771934400,"startTime":"0","endTime":"0","summary":"$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term. Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated Launch of Risto-cel in Sickle Cell Disease . The credit facility matures in early 2033 and bears interest at an annual rate of approximately 10% based on current forward projections for SOFR. The facility does not provide for scheduled amortization payments, and all principal amounts will be due at maturity in early 2033. Beam may prepay loans under the credit facility at any time, subject to customary yield maintenance and prepayment premiums during the early years of the facility. The company is expecting to draw a minimum of $200 million of capital under the overall facility and make mandatory prepayments from certain non-ordinary course proceeds, including proceeds from non-permit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4535","BK4505","LU1861559042.SGD","BK4585","BK4007","BK4588","LU1861558580.USD","LENZ","SCD","BK4139","BEAM","BK4556","BK4611"],"gpt_icon":0},{"id":"2613382737","title":"Beam Therapeutics Inc. published an update to their financial calendar","url":"https://stock-news.laohu8.com/highlight/detail?id=2613382737","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613382737?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:00","pubTimestamp":1771880411,"startTime":"0","endTime":"0","summary":"Beam Therapeutics Inc. will announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program on an investor webcast on Tuesday, February 24, 2026, at 8:00 a.m. ET. The live webcast will be available in the investor section of www.beamtx.com and will be archived for 60 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDLbWPf2X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","IE00BGHQF748.EUR","BK4535","BK4585","LU2095319765.USD","LU0314104364.USD","BEAM","BK4556","LU2210150020.SGD","SG9999014039.USD","BK4112","SG9999014021.USD","SG9999014013.SGD","SG9999014005.SGD","IE00BKPKM429.USD","NDAQ","LU1861559042.SGD","LU2210149790.SGD","LU1861558580.USD","BK4588","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4611"],"gpt_icon":0},{"id":"2613787035","title":"Editas Medicine to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2613787035","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613787035?lang=en_us&edition=fundamental","pubTime":"2026-02-23 22:00","pubTimestamp":1771855200,"startTime":"0","endTime":"0","summary":"ir@editasmed.com. media@editasmed.com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/23/3242678/0/en/Editas-Medicine-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EDIT","BK4556"],"gpt_icon":0},{"id":"2613129204","title":"Beam Therapeutics Initiated at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2613129204","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613129204?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:01","pubTimestamp":1771621260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BEAM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 20, 2026 16:01 ET (21:01 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAM","BK4585","LU1861559042.SGD","BK4535","BK4588","BK4556","BK4007","BK4505","LU1861558580.USD","BK4539","BK4611","BK4139","LENZ"],"gpt_icon":0},{"id":"2612261526","title":"Beam Therapeutics initiated with a Buy at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2612261526","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612261526?lang=en_us&edition=fundamental","pubTime":"2026-02-20 19:56","pubTimestamp":1771588595,"startTime":"0","endTime":"0","summary":"Canaccord analyst Whitney Ijem initiated coverage of Beam Therapeutics (BEAM) with a Buy rating and $74 price target The company’s last 12-18 month...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-initiated-with-a-buy-at-canaccord-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-initiated-with-a-buy-at-canaccord-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BEAM","BK4505","BK4539","BK4585","BK4588","BK4535","BK4007","BK4139","LU1861558580.USD","LU1861559042.SGD","BK4611","BK4556","LENZ"],"gpt_icon":0},{"id":"2612402078","title":"Intellia Therapeutics Inc. to Host Conference Call on Q4 and Full-Year 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2612402078","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612402078?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:31","pubTimestamp":1771504271,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics said it will host a conference call on February 26, 2026 at 8 a.m. ET to discuss its fourth-quarter and full-year 2025 financial results and business updates. The call will be accessible via webcast at link.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL2NmWh8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","NDAQ","LU2210150020.SGD","BK4139","LU1861558580.USD","LU0314104364.USD","NTLA","LU1861559042.SGD","SG9999014005.SGD","SG9999014021.USD","IE00BGHQF748.EUR","BK4112","IE00B64PRP62.GBP","BK4535","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014039.USD","BK4588","BK4556"],"gpt_icon":0},{"id":"2612429049","title":"Press Release: ONE Gas Announces Fourth Quarter and Full Year 2025 Financial Results; Releases Non-GAAP Adjusted Financial Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2612429049","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612429049?lang=en_us&edition=fundamental","pubTime":"2026-02-19 05:20","pubTimestamp":1771449600,"startTime":"0","endTime":"0","summary":"Analyst call and webcast scheduled tomorrow, Feb. 19 at 11 a.m. EST. TULSA, Okla., Feb. 18, 2026 /PRNewswire/ -- ONE Gas, Inc.  today announced its fourth quarter and full year 2025 financial results, which include diluted earnings per share of $1.42 and $4.37, respectively. The Company also provided non--GAAP adjustments to both earnings and its 2026 financial guidance to capture the full impact of a regulatory mechanism intended to mitigate regulatory lag. Adjusted net income was $1.48 per diluted share for the fourth quarter, and $4.48 per diluted share for the full year 2025. For 2026, non--GAAP earnings are expected to range from $306 million to $314 million, or $4.83 to $4.95 per diluted share.\"Our team delivered strong operational and financial results in 2025, reflecting disciplined execution and a commitment to safely serving our communities,\" said Robert S. McAnnally, president and chief executive officer. \"Looking ahead, we see meaningful opportunity in both residential and ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4197","BK4139","BK4556","LU1559883803.SGD","EDIT","LU0566484027.USD","OGS"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}]}}